ASCO25: MSD’s KRAS G12C drug shows early promise in Phase I

MSD’s investigational KRAS G12C inhibitor has shown signs of anti-tumour activity when used both alone and with other oncology drugs.

Jun 3, 2025 - 06:00
ASCO25: MSD’s KRAS G12C drug shows early promise in Phase I
MSD’s investigational KRAS G12C inhibitor has shown signs of anti-tumour activity when used both alone and with other oncology drugs.

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow